Niagen Bioscience (NAGE) Short term Debt (2016 - 2018)

Niagen Bioscience (NAGE) has reported Short term Debt for 3 consecutive years, with $137000.0 the latest figure, recorded in Q4 2018.

• In Q4 2018, Short term Debt fell 55.81% year-over-year to $137000.0; the TTM figure through Dec 2018 stood at $137000.0 (down 55.81% YoY), while the FY2018 annual figure was $137000.0, down 55.81% from the prior year.
• Short term Debt eased to $137000.0 in Q4 2018 per NAGE's latest filing, from $310000.0 in the prior quarter.
• Across five years, Short term Debt topped out at $1.5 million in Q1 2016 and bottomed at $137000.0 in Q4 2018.
• Historically, Short term Debt has averaged $579894.5 across 3 years, with a median of $327000.0 in 2016.
• Annual changes were most pronounced in 2016 — Short term Debt slumped 77.5% — and 2017, when it decreased 9.88%.
• Niagen Bioscience's Short term Debt stood at $344000.0 in 2016, then retreated by 9.88% to $310000.0 in 2017, then tumbled by 55.81% to $137000.0 in 2018.
• Business Quant data shows NAGE's Short term Debt at $137000.0 in Q4 2018, $310000.0 in Q4 2017, and $344000.0 in Q4 2016.